Healthcare data analytics company Health Catalyst (NASDAQ: HCAT) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $76.32 million. On the other hand, next quarter’s revenue guidance of $73.5 million was less impressive, coming in 1.7% below analysts’ estimates. Its non-GAAP profit of $0.06 per share was in line with analysts’ consensus estimates.

Is now the time to buy HCAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Health Catalyst’s third quarter results were met with a positive market reaction as the company delivered revenue above Wall Street expectations despite flat year-over-year performance. Management attributed the quarter’s outcome to solid execution in the Technology segment, which saw continued demand for its applications, and progress in improving gross margins through cost controls and operational changes. CEO Dan Burton highlighted that new client additions and successful client case studies, such as Temple University Health System’s $7.5 million in savings, underscored the real-world impact of its solutions. Management also noted ongoing efforts to optimize the business through restructuring less profitable service contracts and a disciplined approach to capital allocation.

Looking ahead, Health Catalyst’s guidance reflects a cautious stance as the company navigates migration headwinds and evolving client needs. Management emphasized that flexibility in the Ignite platform migration strategy and a renewed focus on applications designed to drive measurable return on investment are central to its outlook. CEO Dan Burton stated, "We are prioritizing growth, profitability, and shareholder return from our existing capabilities and recently acquired assets." The company intends to balance targeted investments in cost management solutions and efficiency initiatives with margin improvement, while acknowledging continued pressure from client budget constraints and changes in the healthcare landscape.

Key Insights from Management’s Remarks

Management credited the quarter’s operating performance to the company’s mix shift toward higher-margin technology solutions and disciplined cost management, while also acknowledging client-driven migration delays and restructuring impacts.

• Technology segment resilience: Growth in the Technology segment, particularly recurring revenue from new and acquired clients, helped offset declines in professional services. Management noted that the applications layer remains a key driver of value and margin improvement, as evidenced by client wins and expanded use cases.
• Leadership team changes: The company strengthened its executive roster, appointing Robbie Hughes as Chief Product Officer and Ben Albert as President and Chief Operating Officer after the Upfront Healthcare acquisition. These moves were designed to boost operational agility and align with strategic priorities for 2026.
• Operational efficiency focus: Ongoing restructuring of professional services contracts, including exiting less profitable arrangements, contributed to higher gross margins and improved adjusted EBITDA. CFO Jason Alliger cited workforce reductions and project-based revenue as key contributors to margin gains in the quarter.
• Ignite migration strategy shift: Health Catalyst adjusted its approach to migrating clients from the legacy DOS platform to Ignite by allowing more flexibility in timing and execution. Management believes this will support client retention and improve satisfaction, even if it slows immediate migration progress.
• Real-world client impact: Solutions such as Power Costing and POP Analyzer enabled clients like Temple University Health System and Entegris Health to achieve multi-million-dollar savings, reinforcing Health Catalyst’s relevance in addressing healthcare cost and efficiency challenges.

Drivers of Future Performance

Health Catalyst’s forward outlook is shaped by migration flexibility, a focus on high-value applications, and continued margin discipline amid a dynamic healthcare environment.

• Migration and retention headwinds: Management expects that ongoing migration from DOS to Ignite will continue to pressure dollar-based retention rates, as certain clients prefer to delay transition due to competing priorities or satisfaction with the legacy platform. Providing more migration flexibility is seen as a way to improve client relationships and retention over the longer term.
• Margin enhancement initiatives: The company is leveraging cost restructuring, increased use of its India operations, and broader integration of artificial intelligence to drive further operating leverage and improve adjusted EBITDA margins. These efforts are aimed at offsetting some of the top-line growth constraints resulting from smaller deal sizes and slower platform migrations.
• Focus on application-driven growth: Health Catalyst plans to prioritize investment in its applications portfolio, particularly those addressing client needs in cost management and ambulatory intelligence. Management sees these solutions as key to driving future revenue growth, client expansion, and measurable ROI for healthcare providers.

Catalysts in Upcoming Quarters

Our analysts will be watching (1) the pace and client response to the Ignite migration flexibility, (2) sustained margin improvement from operational restructuring and broader adoption of AI, and (3) the degree to which new applications in cost management and ambulatory intelligence drive client wins and revenue mix. Execution in retaining and expanding key client relationships will also be instrumental.

Health Catalyst currently trades at $3.06, up from $2.86 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.